Intranasal vaccination with messenger RNA as a new approach in gene therapy: Use against tuberculosis

@article{Lorenzi2010IntranasalVW,
  title={Intranasal vaccination with messenger RNA as a new approach in gene therapy: Use against tuberculosis},
  author={J{\'u}lio CC Lorenzi and Ana Pf Trombone and Carolina Damas Rocha and Luciana P Almeida and Ricardo L Lousada and Thiago Malardo and Isabela Cardoso Fontoura and Renata AM Rossetti and Ana Fl{\'a}via Gembre and Arist{\'o}bolo Mendes Silva and C{\'e}lio Lopes Silva and Arlete A. M. Coelho-Castelo},
  journal={BMC Biotechnology},
  year={2010},
  volume={10},
  pages={77 - 77}
}
BackgroundmRNAs are highly versatile, non-toxic molecules that are easy to produce and store, which can allow transient protein expression in all cell types. The safety aspects of mRNA-based treatments in gene therapy make this molecule one of the most promising active components of therapeutic or prophylactic methods. The use of mRNA as strategy for the stimulation of the immune system has been used mainly in current strategies for the cancer treatment but until now no one tested this molecule… 
Antigen-presenting cells transfected with Hsp65 messenger RNA fail to treat experimental tuberculosis
TLDR
It is demonstrated that antigen-presenting cells transfected with Hsp65 mRNA exhibit a higher level of expression of co-stimulatory molecules, suggesting that Hsp 65 mRNA has immunostimulatory properties.
Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination.
TLDR
This review gives a broad overview about genetic vaccines and mainly focuses on the past and present of mRNA vaccines along with the future directions to bring this potent vaccine platform closer to therapeutic use.
The clinical progress of mRNA vaccines and immunotherapies.
The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of the viral sequence
Cellular Immune Responses to Nine Mycobacterium tuberculosis Vaccine Candidates following Intranasal Vaccination
TLDR
The findings of this study support consideration and further evaluation of an intranasally targeted Apa-based vaccine to prevent tuberculosis.
Exploitation of Synthetic mRNA To Drive Immune Effector Cell Recruitment and Functional Reprogramming In Vivo
TLDR
This study demonstrates how IVT strategies can be combined to recruit and reprogram immune effector cells that have the capacity to fulfill complex biological tasks in vivo.
Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate Hydrolase-II (NTPase-II) Self-amplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP)
TLDR
The results suggest that the combination of self-amplifying RNA and LNP ion would be beneficial to the development of a safe and long-acting vaccine against toxoplasmosis.
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity
TLDR
It is demonstrated that tumor immunity can be achieved via nasal administration of mRNA via intravenous and subcutaneous injections, increasing its potential as a broadly applicable and off-the-shelf therapy for cancer treatment.
Intradermal Electroporation of Naked Replicon RNA Elicits Strong Immune Responses
TLDR
It is demonstrated that naked RREP delivered via intradermal electroporation constitute an immunogenic, safe and attractive alternative immunization strategy to DNA-based vaccines.
Adenovirus-based gene therapy approaches for hemophilia B
TLDR
This study showed that this AdV/SB hybrid-vector system can result in significantly stabilized transgene expression in rapidly dividing hepatocytes in both male and female mice, as well as in a canine model for hemophilia B (three years), and demonstrated that the efficiency of the hybrid- vector system in terms of long-term transGene expression occurred in a dose-dependent manner.
...
...

References

SHOWING 1-10 OF 49 REFERENCES
RNA transfer and its use in dendritic cell-based immunotherapy
TLDR
This review mainly focuses on the potential use of RNA-transduced DCs as a therapeutic strategy in the treatment of cancer, as current studies on thetreatment of infectious d-iseases are just beginning.
Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
TLDR
It is demonstrated here that such treatment is feasible and safe (phase 1 criteria) and an increase in antitumor humoral immune response was seen in some patients, however, a demonstration of clinical effectiveness of direct injection of copy mRNA for antitumors immunotherapy was not shown in this study and must be evaluated in subsequent trials.
Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes
TLDR
A novel, simple technique for efficiently vaccinating mice against tuberculosis (TB), in which a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA.
Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines
TLDR
It is reported here that injection of naked β-globin untranslated region (UTR)-stabilized mRNA coding for β-galactosidase is followed by detectable translation in vivo, and it is shown that such a vaccination strategy primes a T helper 2 type of response which can be enhanced and shifted to a Th1-type immune response by application of recombinant granulocyte/macrophage colony-stimulating factor 1 day after mRNA injection.
Tissue distribution of a plasmid DNA encoding Hsp65 gene is dependent on the dose administered through intramuscular delivery
TLDR
The DNA-Hsp65 was detectable in several tissue types, indicating that DNA- Hsp65 disseminates widely throughout the body, and the biodistribution was dose-dependent, demonstrating an efficient immune response induction and protection against virulent M. tuberculosis challenge.
Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice
TLDR
It is demonstrated that immunotherapy with a plasmid DNA encoding the Mycobacterium leprae 65 kDa heat-shock protein (hsp65) in order to boost the efficiency of the immune system, is a valuable adjunct to antibacterial chemotherapy to shorten the duration of treatment, improve the treatment of latent TB infection and be effective against multidrug-resistant bacilli (MDR-TB).
Protective efficacy of different strategies employing Mycobacterium leprae heat-shock protein 65 against tuberculosis.
TLDR
Liposomes containing DNAhsp65 represent the most promising strategy for the development of a new anti-TB vaccine, with special benefits provided by DNAhSP65 in liposomes and prime-boost strategies.
Therapy of tuberculosis in mice by DNA vaccination
TLDR
It is shown in mice that DNA vaccines, initially designed to prevent infection, can also have a pronounced therapeutic action, and in heavily infected mice, DNA vaccinations can switch the immune response from one that is relatively inefficient and gives bacterial stasis to one that kills bacteria.
Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients
TLDR
It is shown here that direct injection of protamine-protected mRNA is feasible and safe and the significant influence of the treatment on the frequency of immunosuppressive cells, the increase of vaccine-directed T cells upon treatment in a subset of patients together with the demonstration of a complete clinical response encourage further clinical investigation of the protamines-mRNA vaccine.
...
...